Heterocyclic aspartyl protease inhibitors
View Patent ↗Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O) 2 —, —C(═O)—, —O—, —C(R 6 )(R 7 )—, —N(R 5 )— or —C(═N(R 5 ))—; X is —O—, —N(R 5 )— or —C(R 6 )(R 7 )—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O) 2 —, —C(═O)— or —C(═NR 5 )—; U is a bond, —S(O)—, —S(O) 2 —, —C(O)—, —O—, —P(O)(OR 15 )—, —C(═NR 5 )—, —(C(R 6 )(R 7 )) b — or —N(R 5 )—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O) 2 —, —O—, or —N(R 5 )—, U is not —S(O)—, —S(O) 2 —, —O—, or —N(R 5 )—; provided that when X is —N(R 5 )— and W is —S(O)—, —S(O) 2 —, —O—, or —N(R 5 )—, then U is not a bond; and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m 1 agonist or m 2 antagonist.
1. A compound, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
2. A pharmaceutical composition comprising an effective amount of a compound of claim 1 , or a stereoisomer, tautomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutically effective carrier.
3. A pharmaceutical composition comprising an effective amount of a compound of claim 1 , or a stereoisomer, tautomer, or a pharmaceutically acceptable salt thereof, and an effective amount of a cholinesterase inhibitor or a muscarinic m 1 agonist or m 2 antagonist in a pharmaceutically effective carrier.
4. A pharmaceutical composition comprising an effective amount of a compound of claim 1 , or a stereoisomer, tautomer, or a pharmaceutically acceptable salt thereof, and an effective amount of a gamma secretase inhibitor; an HMG-CoA reductase inhibitor or a non-steroidal anti-inflammatory agent.
5. A compound, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
6. A pharmaceutical composition comprising an effective amount of a compound of claim 5 , or a stereoisomer, tautomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutically effective carrier.
7. A pharmaceutical composition comprising an effective amount of a compound of claim 5 , or a stereoisomer, tautomer, or a pharmaceutically acceptable salt thereof, and an effective amount of a cholinesterase inhibitor or a muscarinic m 1 agonist or m 2 antagonist in a pharmaceutically effective carrier.
8. A pharmaceutical composition comprising an effective amount of a compound of claim 5 , or a stereoisomer, tautomer, or a pharmaceutically acceptable salt thereof, and an effective amount of a gamma secretase inhibitor; an HMG-CoA reductase inhibitor or a non-steroidal anti-inflammatory agent.